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Abstract
We report a computational approach that integrates structural bioinformatics, molecular modelling and systems biology to
construct a drug-target network on a structural proteome-wide scale. The approach has been applied to the genome of
Mycobacterium tuberculosis (M.tb), the causative agent of one of today’s most widely spread infectious diseases. The
resulting drug-target interaction network for all structurally characterized approved drugs bound to putative M.tb receptors,
we refer to as the ‘TB-drugome’. The TB-drugome reveals that approximately one-third of the drugs examined have the
potential to be repositioned to treat tuberculosis and that many currently unexploited M.tb receptors may be chemically
druggable and could serve as novel anti-tubercular targets. Furthermore, a detailed analysis of the TB-drugome has shed
new light on the controversial issues surrounding drug-target networks [1–3]. Indeed, our results support the idea that
drug-target networks are inherently modular, and further that any observed randomness is mainly caused by biased target
coverage. The TB-drugome (http://funsite.sdsc.edu/drugome/TB) has the potential to be a valuable resource in the
development of safe and efficient anti-tubercular drugs. More generally the methodology may be applied to other
pathogens of interest with results improving as more of their structural proteomes are determined through the continued
efforts of structural biology/genomics.
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Introduction
The construction and analysis of molecular interaction networks
provides a powerful means to understand the complexity of
biological systems and to reveal hidden relationships between
drugs, genes, proteins, and diseases. In particular, the study of
drug-target networks may facilitate an improved understanding of
the principles of polypharmacology and hence improved rational
drug design [2]. In recent years, several computational method-
ologies have been developed to predict drug-target networks based
on ligand chemistry [4–6], phenotypic changes resulting from drug
perturbation [7–9], or a combination of chemical features of drugs
and sequence features of protein targets [10–12]. Extensive
experimental and computational evaluation has proven that these
methods are valuable for drug repurposing and side effect
prediction. However, these methods are biased towards known
drug-target pairs, which are mainly derived from well-established
human target classes such as G-protein coupled receptors
(GPCRs), which only cover a small portion of the human
proteome. The lack of a broad spectrum of drug-target pairs is
more severe in pathogens than it is in human. For example,
amongst the 3,999 proteins encoded by the Mycobacterium
tuberculosis (M.tb) genome, only nine (cmaA1, cyp51, embA, embB,
embC, folK, InhA, katG and rpoC) have been pharmaceutically
investigated [13]. Thus, drug-target networks that are constructed
from only existing drug targets are retrospective, and less capable
of discovering new druggable targets and predicting off-target
profiles of new compounds on a proteome-wide scale. In addition,
the incompleteness of drug-target data poses questions as to
whether or not the topology of drug-target networks is inherently
modular or random [1].
It is important to construct and analyze a proteome-wide drug-
target network that includes not only the primary targets, but also
all of the potential off-targets of the drugs in the network. Such a
network, if available, would provide unparalleled opportunities for
mapping a comprehensive drug-target space and understanding
the molecular basis of drug efficacy, side- effects and drug
resistance, thereby providing the foundation for the rational design
of polypharmacological (multi-target) drugs. For anti-infectious
drug discovery, where pharmaceutically investigated targets only
represent a small portion of the whole pathogen’s proteome, it is
more challenging to establish a proteome-wide drug-target
network. The linkage of drugs to less exploited proteins such as
virulence factors, transport proteins and transcription factors will
greatly expand the repository of anti-infectious drug targets and
provide new solutions for combating multi-drug and extensively
drug resistant pathogens, and for repurposing existing drugs for
new uses.
Structural bioinformatics provides an alternative and comple-
mentary way to extend drug-target networks to less characterized
proteins on a proteome-wide scale. The structural coverage of a
given pathogen proteome is usually much larger than the
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there are 284 unique proteins in the RCSB Protein Data Bank
(PDB)[14] (as of November 5, 2009), which is more than 30 times
the number of existing pharmaceutical targets for M.tb. By taking
reliable homology models into consideration, it is possible to
increase the structural coverage of the M.tb proteome to
approximately 43%. By taking advantage of this structural
information, we have developed an integrated structural bioinfor-
matics, molecular modelling and systems biology method to
construct and analyze a drug-target interaction network, to
discover novel druggable targets, and to propose new drug
repositioning strategies. Our method is based on the comparison
of the binding sites of existing drugs approved for human use
against the entire structural proteome of the pathogen under
investigation, in order to relate these drugs to new targets. For each
identified drug-target pair, the atomic details of the interaction are
studied using protein-ligand docking.If the protein is in a metabolic
network model, the phenotype change resulting from the drug
perturbation is further investigated using flux balance analysis
(FBA) of the metabolic network. This strategy has been applied to
study several selected drug targets, and proven, both computation-
ally and experimentally, to be a useful tool in drug repositioning
[15], side effect prediction [16,17], and polypharmacological target
discovery [18]. In this paper, we extend this methodology to the
construction of a proteome-wide drug-target network. Compared
with existing methods that are either ligand or target centric, our
method provides a framework to correlate the molecular basis of
protein-ligand interactions to the systemic behavior of organisms.
The proteome-wide and multi-scale view of target and drug space
may shed new light on unsolved issues related to drug-target
networks, and facilitate a systematic drug discovery process, which
concurrently takes into account the disease mechanism and
druggability of targets, the drug-likeness and ADMET properties
of chemical compounds, and the genetic dispositions of individuals.
Ultimately it may help to reduce the high attrition rate during drug
discovery and development.
The continuing emergence of M.tb strains resistant to all
existing, affordable drug treatments means that the development
of novel, effective and inexpensive drugs is an urgent priority.
However, conventional drug discovery is a time-consuming and
expensive process that is poorly equipped in the battle against
tuberculosis. In this study, we apply our integrated approach in
constructing the drug-target network of M.tb, which we refer to as
the ‘TB-drugome’. Using the TB-drugome we first attempt to
characterize all drug-target interactions (i.e., the polypharmaco-
logical space) of the M.tb proteome and to shed new light on
controversial issues surrounding drug-target networks [1–3]. It has
been argued that drug-target networks are similar to random
networks, and that the observed modularity in drug-target
networks may simply be the result of missing links between drugs
and targets [1]. Our results support the idea that drug-target
networks are inherently modular, and further that any observed
randomness is mainly caused by biased target coverage. Then we
introduce a new concept, the target chemical druggability index
(TCDI), which we use to determine the chemical druggability and
prioritization of a protein as a drug target, and to characterize the
potential of a drug as a polypharmacological lead compound. The
TB-drugome reveals not only that many existing drugs show the
potential to be repositioned to treat tuberculosis, but also that
many currently unexploited M.tb proteins may be highly druggable
and could therefore serve as novel anti-tubercular targets. The
TB-drugome is publically available (http://funsite.sdsc.edu/
drugome/TB) and has the potential to be a valuable resource
for the development of safe and efficient anti-tubercular drugs.
Structural biology and structural genomics efforts continue to
increase the structural coverage of the M.tb proteome [19–21], as
well as those of other pathogens. This will improve the robustness
of the TB-drugome and facilitate the application of this
methodology to other pathogens. We hope that the application
of the drugome concept will revitalize our way of thinking about
how drug discovery is approached, something which is urgently
needed if we wish to succeed in this on-going battle against multi-
drug and extensively drug resistant infectious diseases.
Results
A drug binding site database
A total of 274 different drugs approved for human use in the
United States and Europe were identified in the RCSB Protein
Data Bank (PDB) [14]. While the majority of these drugs were
only co-crystallized with a single protein structure, many drugs
were co-crystallized with more than one structure, bringing the
total number of drug binding sites in the PDB to 962 (see the
Supporting Information, Table S1). Many of these structures were
derived from the same protein in different source organisms, and
so the number of binding sites per drug is not a good indicator of
drug promiscuity. In order to overcome this issue, the number of
unique proteins co-crystallized with each drug was determined
(Figure 1). While the vast majority of the drugs (194/274) had only
been co-crystallized with a single protein, several had been co-
crystallized with a number of different proteins, often from
completely different folds. With a total of 11, 9, 8 and 7 different
binding sites, the drugs niacinamide, acarbose, alitretinoin and
indomethacin, respectively, were co-crystallized with the greatest
number of different proteins. The distribution of the drug
connections of co-crystallized proteins is close to a power-law
distribution (Supporting Information, Figure S1). However, most
of the proteins are only co-crystallized with a single drug. Only five
proteins are co-crystallized with two drugs, and no proteins are co-
crystallized with more than two drugs. It is not clear whether or
not target connections in the PDB are scale-free.
TB-drugome: A reliable and unbiased protein-drug
interaction network
The TB-drugome, a structural proteome-wide drug-target
network of M.tb, was constructed by associating the putative
Author Summary
The worldwide increase in multi-drug resistant TB poses a
great threat to human health and highlights the need to
identify new anti-tubercular agents. We have developed a
computational strategy to link the structural proteome of
Mycobacterium tuberculosis, the causative agent of tuber-
culosis, to all structurally characterized approved drugs,
and hence construct a proteome-wide drug-target net-
work – the TB-drugome. The TB-drugome has the potential
to be a valuable resource in the development of safe and
efficient anti-tubercular drugs. More generally, the pro-
teome-wide and multi-scale view of target and drug space
may facilitate a systematic drug discovery process, which
concurrently takes into account the disease mechanism
and druggability of targets, the drug-likeness and ADMET
properties of chemical compounds, and the genetic
dispositions of individuals. Ultimately it may help to
reduce the high attrition rate in drug development
through a better understanding of drug-receptor interac-
tions on a large scale.
TB-Drugome
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of approved drugs for which structural information about the
target was available. The premise is that two entirely unrelated
proteins can bind similar ligands if they share similar ligand
binding sites. In this way, a M.tb protein can be connected to a
drug through the drug’s target, irrespective of whether that protein
target is from human or another organism. The binding site
comparison software SMAP [22–24], was used for this purpose in
an all-drug-against-all-target manner (see the Methods section). In
a previous benchmark study, SMAP outperformed most of the
existing ligand binding site comparison algorithms [22,24].
Moreover, several predictions from SMAP have been experimen-
tally validated [15,18,25]. Thus SMAP has proven a useful tool to
identify the off-targets of existing drugs. The resulting TB-
drugome network is shown in Figure 2 and consists of M.tb
proteins (blue circles) connected to drugs (red circles), where a
single connection indicates binding site similarity between any of
the structures of the connected M.tb protein, and any of the
binding sites of the connected drug. The TB-drugome is highly
connected, indicating that many binding site similarities were
observed between M.tb proteins and drug targets, even though
those proteins had different overall structures.
The number of edges in the TB-drugome network depends on
the confidence level of the prediction. To determine the SMAP P-
value threshold that gives a balanced false positive and negative
rate in the TB-drugome, the average connectivity of the drugs was
plotted against the SMAP P-value. A turning point in the curve
exists for a SMAP P-value of 1.0e-5 (Figure 3), i.e., the connectivity
of the drugs changes only slightly with a SMAP P-value of less than
1.0e-5, but rapidly increases when the P-value is greater than 1.0e-
5. The use of a SMAP P-value threshold greater than 1.0e-5 will
therefore reduce the false negative rate, but dramatically increase
the false positive rate when detecting similar ligand binding sites.
Thus, a SMAP P-value of 1.0e-5 was selected as a threshold for
network construction, and was used throughout this study. Based
on the previous SMAP benchmark study [22,24], the false positive
rate is approximately 5% when the SMAP P-value is close to 1.0e-
5. Thus, it is estimated that the false positive rate of connections is
approximately 5% in the TB-drugome.
In the TB-drugome, 123 of the 274 drugs are connected to 447
of the 1,730 proteins (284 PDB structures plus 1,446 homology
models). Thus, it is estimated that around 40% of these 274
approved drugs, or their associated compound libraries, may be
active against around 25% of the M.tb structural proteome, greatly
expanding the existing anti-tubercular drug-target space. Unlike
other drug-target networks [1–3], the TB-drugome is not biased
towards certain gene families. The largest family in the TB-
drugome is cytochrome P450, which consists of 20 proteins,
comprising approximately 4.5% of the connected proteins and 1%
of all proteins in the TB-drugome, respectively. The average
Figure 1. The numbers of unique proteins co-crystallized with approved drugs in the PDB.
doi:10.1371/journal.pcbi.1000976.g001
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almost twice the predicted value of 6.3 for drug-target networks
[1]. Despite the high degree of drug connectivity, the modularity
of the network is maintained, as shown in the next section.
The TB-drugome is a scale-free and modular network
Reliable and unbiased drug-target networks may shed new light
on the controversial issues surrounding the underlying topological
structure of drug-target networks. It has been argued that drug-
target networks are similar to random networks, and that the
observed modularity in drug-target networks may simply be the
result of missing links between drugs and targets [1]. Topological
analysis of the TB-drugome provides evidence for the modularity
of drug-target networks. Although the average connectivity of
drugs is much higher (Figure 3) than that predicted for a drug-
target network in which the targets are pharmaceutically
annotated [1], the distribution of target connectivities follows a
power-law distribution regardless of P-value threshold (Figure 4A
and Table 1). That is, most targets have few connections, but a
small number of targets are connected to a large number of drugs.
This is also true for drug connectivity (Supporting Information,
Figure S2 and Table S6). This observation strongly suggests that
proteome-scale drug-target networks are not random. This scale-
free property is not sensitive to the systematic noise introduced by
the increased number of false positive edges that result from an
increase in the P-value threshold, indicating that the connections
between proteins and drugs are not completely random. The
connections reflect the underlying evolutionary, geometric and
physicochemical relationships between the M.tb proteins and the
drug targets. In contrast, if the edges in the network were random,
this scale-free property would break down (Figure 4B and Table 1).
Similarly, the false negative rate also has little effect on the
topology of the network since the power-law distribution remains
consistent when the number of false negatives is increased as a
result of decreasing the P-value threshold.
Besides being scale-free, the TB-drugome network is modular,
as measured by the clustering coefficient. As shown in Table 2, the
clustering coefficients of both the targets and the drugs are almost
twice those of the corresponding random networks. Moreover,
since there is no significant change in the clustering coefficient
when using different SMAP P-value thresholds to define the
network connectivity, this implies that an underlying architecture
exists in the TB-drugome. The modularity of the TB-drugome is
also measured by the largest connected component (nLCC). The
nLCC values for M.tb targets and drugs are 0.93 and 0.84,
respectively, compared to nLCC values of 0.97 and 1.0,
respectively, for a random network (Supporting Information,
Figure S3). This modularity becomes more obvious for high
confidence networks that are derived from P-value thresholds of
1.0e-6 and 1.0e-7.
Since the 274 structurally characterized drugs only comprise
around 20% of all approved drugs, it is interesting to investigate
the effects of increasing drug structural coverage on the properties
of the network. To address this question, we randomly selected a
subset of the 274 structurally characterized drugs to see how the
structural coverage of drug-target complexes affects the power-law
Figure 2. A protein-drug interaction network to illustrate similarities between the binding sites of M.tb proteins (blue), and binding
sites containing approved drugs (red). A SMAP P-value threshold of 1.0e-5 was used.
doi:10.1371/journal.pcbi.1000976.g002
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when the number of drug-target complexes drops to 20% of the
total number present in the PDB, there are no significant changes
in the network properties of the TB-drugome (Supporting
Information, Figure S4, Table S7 and S8). Thus, it is expected
that the scale-free properties and modularity observed in the TB-
drugome will not be affected by an increase in the number of drug-
target complex structures.
One factor that may contribute to the randomness of existing
ligand-based drug-target networks is target bias towards several
gene families, for instance, G-protein coupled receptors. Proteins in
the same gene family tend to cluster together; therefore, if such gene
families dominate a network, then a large nLCC value is easily
obtained and the power law distribution breaks down. It is to be
expected that the topological properties of drug-target networks will
change once extended to include the entire proteome. The current
incompleteness of drug-target networks is not only due to the
missing links between drugs and targets, but also due to the biased
and limited coverage of target space. However, as this coverage
improves we anticipate that power-law behaviour will be preserved.
Highly connected proteins are potential chemically
druggable targets
To our knowledge, there are currently only nine M.tb proteins
that have been validated as drug targets; cmaA1 (Rv3392c), cyp51
(Rv0764c), embA (Rv3794), embB (Rv3795), embC (Rv3793),
folK (Rv3606c), InhA (Rv1484), katG (Rv1908c) and rpoC
(Rv0668) [13]. According to the TB-drugome there are numerous
other drug targets yet to be exploited. An important question in
drug discovery is whether or not a biologically validated target is
able to bind drug-like molecules with high affinity, i.e., whether or
not the target is chemically druggable. Although chemical
druggability can be predicted from the ligand binding site of a
protein [26], there is still a big gap between identifying lead
compounds and developing safe drugs. Analysis of the TB-
drugome not only provides molecular insights into chemical
druggability, but also suggests existing drugs that could either be
directly repurposed or act as lead compounds. Here we introduce
a new Target Chemical Druggability Index (TCDI), which is
orthogonal to biological essentiality, and directly links target and
Figure 3. The average number of connections per drug in the TB-drugome against the SMAP P-value threshold.
doi:10.1371/journal.pcbi.1000976.g003
TB-Drugome
PLoS Computational Biology | www.ploscompbiol.org 5 November 2010 | Volume 6 | Issue 11 | e1000976drug space. After the drug target has been biologically validated as
an essential gene, the TCDI may be applied to determine if it is a
suitable candidate for medicinal chemistry efforts. The TCDI is
determined by the number of unique drugs (those with a 2D
Tanimoto coefficient to one another of less than 0.75) that are
connected to a protein in the TB-drugome. In this way, it is
possible to prioritize the chemically druggable targets on a
proteome-wide scale. In the TB-drugome, there are 165 proteins
with a TCDI of greater than 2. Those proteins with a TCDI of
greater than 8 are listed in Table 3. Since most of these proteins
have not been pharmaceutically investigated, their propensity to
bind drug-like molecules should be determined experimentally.
Although gene essentiality is not necessarily correlated with
chemical druggability, it is interesting to investigate whether or not
those proteins with a large TCDI are crucial for bacterial survival
or virulence. If a gene is both essential and chemically druggable, it
will be an ideal target for drug development. The biological roles
of these proteins were determined primarily from the literature.
Since several of the proteins listed in Table 3 are involved in
metabolism, it is possible to investigate the effects of their knockout
by carrying out flux balance analysis (FBA) using a proteome-wide
network model of M.tb metabolism. The GSMN-TB model [27]
was selected to simulate in vivo conditions, while the iNJ661 model
[28] was selected to simulate in vitro conditions.
Most of the proteins in Table 3 with known functions are
essential for bacterial survival, as predicted by metabolic
simulation, or validated by experiments. The top ranked protein,
Rv3676, encodes the cAMP receptor protein/fumarate and nitrate
reductase (CRP/FNR) transcriptional regulator. Members of the
CRP/FNR class of transcriptional regulators respond to environ-
mental conditions associated with low oxygen stress and starvation,
and may play an important role in reactivating dormant bacilli.
The importance of the M.tb CRP/FNR transcriptional regulator
has been demonstrated through knockout studies. Indeed, deletion
of this gene is known to cause growth defects in laboratory
medium, in bone marrow derived macrophages and in a mouse
model of tuberculosis [29]. 22 unique drugs are predicted to be
potential lead compounds targeting CRP/FNR. As shown in
Figure 5, besides the known cAMP binding site (site A), a second
binding site (site B) is identified in the DNA binding domain. This
finding provides opportunities to design drug conjugates or
combination therapies to inhibit this protein. The M.tb protein
with the second highest TCDI is InhA (enoyl-acyl carrier protein
reductase), which is actually the target of the front-line anti-
Figure 4. Fitting of the distribution of target connections to a power-law distribution for (A) the TB-drugome and (B) a random
network. A SMAP P-value threshold of 1.0e-5 was used.
doi:10.1371/journal.pcbi.1000976.g004
Table 1. Fitness of the power law distribution for protein targets in the TB-drugome and corresponding random network at
different SMAP P-value thresholds.
TB-drugome Random Network
SMAP P-value k log(a)R
2 P-value k log(a)R
2 P-value
1.0e-3 21.3645 6.5601 0.8335 ,0.0001 0.26237 2.6708 0.0080 0.69172
1.0e-4 21.6141 6.3413 0.9262 ,0.0001 20.7184 4.7086 0.1395 0.18843
1.0e-5 21.7478 5.6507 0.9436 ,0.0001 21.8292 5.6489 0.6204 0.00399
1.0e-6 21.6231 4.6890 0.8321 ,0.0001 21.6799 4.8057 0.6063 0.02281
1.0e-7 21.4326 3.9845 0.8930 ,0.0001 21.4956 4.1041 0.6271 0.03381
doi:10.1371/journal.pcbi.1000976.t001
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effect of isoniazid depends on its conjugation with the NAD co-
factor. The development of isoniazid-resistant M.tb strains has
promoted the discovery of a number of direct inhibitors of InhA
[31]. Most of the predicted drug binding sites are located in the
substrate binding site of InhA, and therefore serve as potential
leads for direct InhA inhibitors. Indeed, the prediction that InhA
can be directly inhibited by an existing drug has already been
experimentally validated. Both an in vitro bacterial growth study
and an enzyme kinetic assay supported our previous in silico
prediction that Comtan, a drug used in the treatment of
Parkinson’s disease, could potentially be repurposed to target
InhA directly [15]. Thus the prediction that InhA is a highly
druggable target is supported by existing experimental data, in
addition to common clinical practice.
There are a number of M.tb proteins that, although not
predicted to be essential, may play important roles in the host-
pathogen interaction. The protein with the third highest TCDI is
Rv1264, a class III adenylyl cyclase which synthesizes cAMP from
ATP in response to sensing the mildly acidic pH of the host
macrophage phagosome. Biochemical studies of Rv1264 have
suggested that it may be crucial for the M.tb host-pathogen
interaction, thereby highlighting it as another potentially interest-
ing drug target [32]. The predicted drug binding site is located in
the dimerization interface of the regulatory domain (Supporting
Information, Figure S5). Since dimerization is critical for the
function of adenylyl cyclase, it is speculated that the inhibition of
its association may disrupt its function [33]. Other proteins that
are involved in the host-pathogen interaction include Rv2413c
[34], narL [35,36], and lprG [37]. A new strategy emerging to
combat drug resistant pathogens is to target the pathways involved
in host-pathogen interactions [38]. The identification of druggable
targets that contribute towards pathogenicity (e.g., proteins
involved in two-component regulatory systems [39,40]) and the
host-pathogen interface may present new opportunities for the
discovery of novel therapeutics effective against tuberculosis.
Several other non-essential genes may contribute to drug
resistance mechanisms exhibited by M.tb. For example, Rv1272c is
an efflux pump that detoxifies antibiotics. Combination therapy
using antibiotics mixed with efflux pump inhibitors could therefore
be a practical solution for increasing the efficacy of antibiotics
[41]. In addition, the TB-drugome may provide clues about the
biological roles of proteins with unknown functions. Since Rv0856
is predicted to bind to antibiotics such as minocycline and
rifampin, it is possible that this protein is involved in the
detoxification of these antibiotics.
Highly connected drugs are candidates for multi-target
therapeutics
The TB-drugome reveals that, of the 274 different drugs
investigated, 92 drugs could potentially inhibit more than one M.tb
protein. This is advantageous both in terms of drug effectiveness
and preventing the development of drug resistance. Indeed, large-
scale functional genomics studies in model organisms have shown
that the vast majority of single-gene knockouts actually exhibit
little or no effect on phenotype [42]. The concept of ‘synthetic
lethality’ - genes that are not essential individually, but are
essential in combination - uncovers a whole new plethora of drug
targets that may have been overlooked due to their non-essentiality
in individual gene knockout studies. Synthetic lethality explains the
Table 2. Clustering coefficients for protein targets and drugs
in the TB-drugome and corresponding random network at
different SMAP P-value thresholds.
Target Drug
SMAP
P-value TB-drugome
Random
network TB-drugome
Random
network
1.0e-4 0.703 0.342 0.783 0.417
1.0e-5 0.663 0.318 0.676 0.351
1.0e-6 0.643 0.339 0.556 0.273
1.0e-7 0.765 0.354 0.786 0.313
doi:10.1371/journal.pcbi.1000976.t002
Table 3. Genes in the TB-drugome with a TCDI of greater than 8, and their in silico, in vitro, and in vivo essentialities, and potential
as a drug target.
Gene TCDI in silico essentiality in vitro Essentiality in vivo Essentiality Useful Target
GSMN-TB iNJ661
Rv3676 22 X X Essential [86] [29]
inhA (Rv1484) 19 Essential Essential [87]
Rv1264 15 X Non-essential [88]
Rv2413c 13 X X [34]
ffh (Rv2916c) 11 X X Essential [89] [90]
narL (Rv0844c) 10 X X [36], [35]
lprG (Rv1411c) 10 X X Essential [91], [92] [37]
Rv1272c 10 Non-essential X Essential [92] [93]
Rv0856 9 X X Function unknown
Rv3644c 9 X X [90]
Rv0435c 9 X X [90]
proC (Rv0500) 9 Non-essential Essential Essential [89] [94]
The gene is marked with an ‘x’ if it was not present in the GMMN-TB or iNJ661 reconstructed metabolic networks.
doi:10.1371/journal.pcbi.1000976.t003
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discovered serendipitously over the years, including D-cycloserine,
beta-lactam antibiotics, fosfomycin and fluoroquinolone antibiotics
[43]. Furthermore, inhibition of two or more proteins that are
essential individually is advantageous from a drug resistance
perspective. Indeed, while pathogens are able to rapidly acquire
resistance to single target agents through mutations in the target
protein, it is much more difficult to acquire resistance to multiple
target agents, since a mutation in one of the essential target
proteins would not confer any selective advantage over the
wildtype [44].
Some drugs in the TB-drugome have the potential to inhibit a
large number of different M.tb proteins simultaneously. It is
important to note that there are two types of connections in the
TB-drugome; those that involve proteins belonging to the same
fold, and those that involve proteins belonging to different folds.
The detection of functional relationships between proteins
belonging to the same fold is considered to be a trivial task
because it can be achieved by simply using conventional sequence
and structure comparison tools. It is more interesting and novel to
relate proteins across fold space, i.e., when the primary drug target
and its off-target(s) do not share similar global structures. Such
cross-fold connections constitute around 60% of all connections in
the TB-drugome (see Tables S2 and S3 in the Supporting
Information for a full list of cross-fold connections in the TB-
drugome). The 15 most highly cross-fold connected drugs are
listed in Table 4, along with the names of the solved M.tb proteins
to which they are connected. With 98 cross-fold connections,
alitretinoin, a drug used to treat cutaneous lesions in patients with
Kaposi’s sarcoma, is the most highly connected drug. The solved
M.tb proteins to which it is connected include bioD, InhA and
purN, all of which are predicted to be essential in vivo by a
metabolic network reconstruction of M.tb [27]. With 63 different
cross-fold connections, levothyroxine, a drug used to treat
hypothyroidism, is the second most highly connected drug.
Further investigation revealed that it was the structure of
levothyroxine bound in the binding site of serum albumin that
was determined to be significantly similar to many of the 63
different M.tb binding sites. This is interesting because, as a non-
specific binder of steroid hormones and a transport protein for
various fatty acids, serum albumin is known to be a highly
promiscuous protein [45]. While it is not necessarily a useful result
for the purposes of this study, the fact that SMAP is able to detect
similarities between the binding site of serum albumin and the
binding sites of multiple other proteins at least provides some
validation that it is working correctly. Serum albumin also
accounts for all 24 connections between the drug propofol and
various different M.tb proteins. Note that although serum albumin
is also listed as an intended target of methotrexate, this drug has
not actually been cocrystallized with serum albumin in the PDB,
and so this does not account for its high connectivity.
The front-line anti-tubercular agent rifampin is listed as the fifth
most highly connected drug in Table 4. The structure of its known
M.tb target, DNA-directed RNA polymerase (rpoC) has not been
solved, therefore explaining why it is not listed as a potential target
in Table 4. However, a suitable homology model of rpoC was
identified in ModBase, based on RNA polymerase from the
eubacterium Thermus thermophilus. The fact that rifampin has
connections with six other solved M.tb proteins in Table 4 suggests
that it may be mediating some of its anti-tubercular effects through
proteins other than its known target, rpoC. A recent study showed
that rifampin is able to bind to the NAD binding site of ADP-
ribosyl transferase [46], which is ranked highly at 24/962 with a
SMAP P-value of 4.32e-4. Rifampin is predicted to bind to the
NAD and FAD binding sites of InhA and lpdA, respectively. Both
of these predictions are supported by the compound association
listed in the TDR target database [47]. Since the off-targets of
rifampin may be involved in drug metabolism and detoxification,
the proteome-wide identification of off-targets may provide
molecular insight into the understanding of drug resistance
mechanisms.
A literature search of the M.tb proteins listed in Table 4 reveals
that most of them are potentially novel targets for the development
of anti-tubercular therapeutics. For instance, aroF (chorismate
synthase), aroG (chorismate mutase) and aroK (shikimate kinase)
are attractive targets because they are all involved in the shikimate
pathway, which is both essential for the viability of M.tb, and
absent from humans [48]. LppX is a lipoprotein required for the
translocation of complex lipids to the outer membrane, and
disruption of the lppX gene has been shown to result in
attenuation of virulence of the tubercle bacillus [49]. Another
protein that is essential for the pathogenesis and virulence of M.tb
is the sigma factor sigC, which controls the environment
dependent regulation of transcription [50]. A potential target
against M.tb persistence is the universal stress protein, TB31.7,
which is required for the entry of the tubercle bacillus into the
chronic phase of infection in the host [51]. These are merely a few
examples of the many potentially interesting M.tb targets listed in
Table 4. Furthermore, there are likely to be many more attractive
targets in the form of homology models, which have not been
investigated here.
Since many of the genes encoding the M.tb proteins listed in
Table 4 are involved in metabolism, it is possible to investigate the
effects of their knockout using a proteome-scale network model of
M.tb metabolism. The GSMN-TB model [27] was selected for this
purpose due to its ability to simulate in vivo conditions. Those genes
that were present in the GSMN-TB model, and whose knockout
could therefore be simulated, are underlined in Table 4. Those
genes whose knockout resulted in a maximal theoretical growth
rate of zero or close to zero were considered essential and have
been highlighted in bold. All of the drugs in Table 4, with the
exception of amantadine and lopinavir, are predicted to
potentially inhibit one or more essential metabolic proteins with
solved structures. In particular, the anti-HIV therapeutic ritonavir
could potentially inhibit a total of five different essential proteins
involved in metabolism; accD5 (propionyl-CoA carboxylase),
aroK (shikimate kinase), fabH (3-oxoacyl-(acyl carrier protein)
Figure 5. Predicted drug binding sites and poses in M.tb CRP/
FNR. The AMP binding site is labelled ‘A’. An alternative binding site in
the DNA binding domain is labelled ‘B’. The protein is represented as a
green ribbon model. Drugs are represented as stick models. Atoms of C,
O, N, and S are colored grey, red, blue and yellow, respectively.
doi:10.1371/journal.pcbi.1000976.g005
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3-phosphoglycerate dehydrogenase). Amantadine has connections
to homology models only and so was excluded from this study.
Although lopinavir may not inhibit any essential metabolic
proteins, some of the proteins that it could potentially inhibit may
be interesting anti-tubercular targets. For instance, pknG, a
eukaryotic-type protein kinase, has been shown to support the
survival of mycobacteria in host cells [52], and is required for the
intrinsic resistance of mycobacterial species to multiple antibiotics
[53]. In addition, the GSMN-TB model was used to simulate
multiple gene knockouts and therefore the effect of a single drug
inhibiting multiple metabolic proteins simultaneously. For each
drug (excluding amantadine and lopinavir), the combined
knockout of all metabolic genes listed in Table 4 resulted in zero
or close to zero biomass (except for the case of levothyroxine,
where combined inhibition of bioD (essential) and thyX (non-
essential) resulted in growth). More studies are required to verify
this prediction.
The multi-drug-multi-target space of polypharmacology
If all members of a set of proteins can bind to the same set of
multiple drugs, this set of proteins could provide interesting targets
for polypharmacological drugs. Such polypharmacological drug
targets can be derived from the TB-drugome. Indeed, several
multi-drug-multi-target clusters are distinguishable within the
drug-target matrix shown in Figure 6. The three largest clusters
are the cytochrome P450s (CYP), protein kinases (PKN), and
polyrenyl-diphosphate/polyrenyl synthases (GRC). As promiscu-
ous metabolizing enzymes, the cytochrome P450s bind to multiple
drugs, while the protein kinases and polyrenyl-diphosphate/
polyrenyl synthases bind human protein kinase inhibitors and
farnesyl-diphosphate synthase inhibitors, respectively. Although
this result is not surprising, the fact that similar drugs and similar
targets are clustered together provides further validation of the
TB-drugome.
An interesting cluster is ilvG (acetolactate synthase), asd
(aspartate-semialdehyde dehydrogenase), fadE13 (acyl-CoA dehy-
drogenase) and Rv0037c (MFS-type transporter), all of which are
predicted to bind to HIV-1 protease inhibitors. There is a major
problem with coincidence of HIV and tuberculosis in sub-Saharan
Africa. Indeed, HIV and tuberculosis form a deadly combination,
each accelerating the other’s progress. Since HIV weakens the
immune system, HIV-positive individuals are much more
susceptible to developing an active form of tuberculosis and
becoming infectious [54]. Co-administration of existing anti-TB
and anti-HIV therapeutics is undesirable due to adverse side-
effects. Therefore, the finding that an anti-HIV therapeutic can
actually be used to treat both HIV and TB simultaneously would
be of great interest. It is also worth noting that five of the top 15
most highly connected drugs in the TB-drugome, which are listed
in Table 4, are also HIV-1 protease inhibitors.
Discussion
A new method to construct a structural proteome-wide
drug-target network
All existing drug-target networks have been constructed from
annotated drug-target pairs or predicted based on the chemical
Table 4. The 15 most highly connected drugs in the TB-drugome.
Drug Intended Targets
Total Number of
Connections
Connected M.tb proteins with Solved
Structures
Alitretinoin Retinoic acid receptor RXR-a, b & c, retinoic acid receptor
a, b & c-1&2, cellular retinoic acid-binding protein 1&2
98 aroG, bioD, bpoC, cyp125, embR, glbN, InhA, lppX,
nusA, pknE, prcA/prcB, purN, Rv1264, Rv3676
Levothyroxine Transthyretin, thyroid hormone receptor a & b-1, thyroxine-
binding globulin, mu-crystallin homolog, serum albumin
63 argR, bioD, blaI, ethR, glbN, glbO, kasB, lrpA, nusA,
prrA, Rv1264, Rv3676, secA1, thyX
Methotrexate Dihydrofolate reductase, serum albumin 48 argB, aroF, cmaA2, cyp121, cyp51, lpd, mmaA4,
panC, Rv3676, TB31.7
Estradiol Estrogen receptor 38 argB, bphD, cyp121, cysM, InhA, mscL, pknB,
Rv1264, Rv3676, sigC
Rifampin DNA-direct RNA polymerase beta chain, orphan nuclear
receptor PXR, multidrug resistance protein 1
34 InhA, lpdA, lppX, mscL, ptpB, Rv3676
4-hydroxytamoxifen Estrogen receptor, estrogen receptor b, epoxide hydrolase
2, multidrug resistance protein 1, thymidine phosphorylase
33 argB, cysM, InhA, katG, lppX, pknB, pknE, Rv1264,
Rv1941, Rv3676
Amantadine Dopamine receptor D1A&2, matrix protein 2 32 (homology models only)
Raloxifene Estrogen receptor, estrogen receptor b 28 deoD, InhA, mbtK, pknB, pknE, prcA/prcB, Rv1264,
Rv3676, secA1, sigC
Propofol Serum albumin, gamma-aminobutyric-acid receptor subunit
alpha-1, fatty-acid amide hydrolase
24 clpP, glbN, InhA
Indinavir HIV-1 protease, Gag-Pol polyprotein 23 InhA, lpdA
Ritonavir HIV-1 protease 22 accD5, aroK, fabH, lpdA, panC, serA1, TB31.7
Darunavir HIV-1 protease, Gag-Pol polyprotein 22 cyp124, devB, InhA, lpdA, panC
Lopinavir HIV-1 protease, Gag-Pol polyprotein, protease 22 lpdA, nrdB, pknG, tpiA
Penicillamine Caspase-1, Ig kappa chain V-III region GOL 20 groEL, InhA, nusA, Rv1264, Rv3676
Nelfinavir HIV-1 protease 20 fabH, pknG, serA1
The intended targets of the drugs are given as well as the solved M.tb proteins to which they are connected in the network. Those genes that were present in the
GSMN-TB metabolic reconstruction are underlined and, of these, those whose knockout resulted in a maximal theoretical growth rate of zero or close to zero have been
highlighted in bold. Note that only cross-fold connections are considered here.
doi:10.1371/journal.pcbi.1000976.t004
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they only include the limited number of human drug targets that
have been pharmaceutically investigated, i.e., a small, highly
biased subset of the human proteome. The lack of a broad
spectrum of drug-target pairs is more severe in pathogens than it is
in human. For example, among the 3,999 proteins encoded in the
M.tb genome, only nine proteins (cmaA1, cyp51, embA, embB,
embC, folK, InhA, katG and rpoC) have been pharmaceutically
investigated [13]. Conventional methods can only build a drug-
target network based on these nine proteins and their associated
ligands. Thus, they cannot generate a comprehensive drug-target
network like the TB-drugome. The chemical systems biology
strategy applied in this paper provides a complementary approach
to constructing a structural proteome-wide drug-target network.
To our knowledge, the TB-drugome is the first drug-target
network that covers this many proteins in the TB structural
proteome and all drugs that have been structurally characterized.
The TB-drugome includes 50 times more proteins than the
existing TB targets, and more than 100 drugs that have not been
investigated for tuberculosis treatment. Compared with existing
methods that require information about drug-target pairs, one of
the unique features of the TB-drugome is that the relationship
between two proteins can be established by their ligand binding
site similarity, independent of their associated ligands. This feature
not only greatly extends target coverage to those proteins with
unknown or less characterized ligands, but also includes drugs that
may not necessarily be used to target TB proteins directly. Thus,
the resulting network is more complete and less biased. Since the
TB-drugome includes a large number of poorly characterized or
uncharacterized proteins, it may provide greater insight into the
progressive drug discovery process than existing drug-target
networks. Indeed, it may aid the discovery of novel druggable
targets that have not been explored previously, guide medicinal
chemists to design compounds with desirable specificity to avoid
unwanted side effects, and promote the rational design of
polypharmacological drugs by selecting multiple suitable targets.
Coincident with recent efforts involving screening compound
libraries of existing human drug targets to treat anti-infectious
diseases [25,55,56], our method will be particularly useful in
genome-wide compound profiling, lead generation from existing
drug-like molecules, and identifying the molecular targets of active
compounds. It is not feasible to achieve such goals using existing
drug-target networks in cases where the actual molecular targets or
their ligands are unknown.
Towards a proteome-wide multi-scale protein-drug
interaction network
Notwithstanding, there are major limitations in the methodol-
ogies applied in this study. Firstly, the structural coverage of the
M.tb proteome is limited. Currently only 7.2% of M.tb proteins
have solved structures in the PDB. The use of reliable homology
models increases the structural coverage to around 43%.
However, each homology model consists of only a single chain
rather than the entire biological unit, which could be a multi-
polypeptide chain complex. As a result interesting binding sites
located in the interface between the chains may be missed.
Similarly, only around 20% of all drugs approved for human use
have actually been solved with a protein target structure in the
PDB. Coverage of drug space can be increased by using crystal
structures or homology models of proteins that are known targets
of approved drugs, but for which there are no structures with the
drugs bound. For instance, the additional inclusion of homology
models of GPCRs would double the number of targets.
Two proteins may bind to similar ligands even though their
binding pockets may have varied geometrical and physicochemical
properties. Such proteins may be sequence homologues, have
similar structures, or belong to entirely different folds. For the first
two scenarios, SMAP is more sensitive than conventional sequence
and structural comparison methods in detecting ligand binding site
similarity [24]. For the third scenario, SMAP takes into account
residue mutations and geometrical variances within the binding
site, therefore making it a sensitive algorithm for ligand binding
site similarity searches. However, a fraction of true positives may
still be missed in all three scenarios. Despite the existence of false
negatives in the drug-target network, the TB-drugome has
generated abundant testable hypotheses. From the point of view
Figure 6. Hierarchal clustering of drug-target binding profiles in the TB-drugome. The grid is colored red if there is a connection between
a protein and a drug in the TB-drugome, otherwise, it is colored blue. Each row and column in the matrix corresponds to a binding profile of a drug
and a protein, respectively. The three largest clustered gene families are the cytochrome P450s (CYP), protein kinases (PKN), and polyrenyl-
diphosphate/polyrenyl synthases (GRC). A new gene cluster (HIV) is predicted to bind to HIV-1 protease inhibitors. For the purpose of clarity, a SMAP
P-value threshold of 1.0e-6 has been used.
doi:10.1371/journal.pcbi.1000976.g006
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false positive rate than to reduce the false negative rate. The
further construction of reliable proteome-wide drug-target net-
works will benefit from the integration of diverse techniques such
as ligand-centric methods [4,57] and omics data such as gene
expression profiles in response to drugs [9]. The integration of
multiple data resources will not only increase the coverage of the
network, but also the confidence of the predictions made, through
the use of consensus results.
Aside from the false negatives that result from the limited
structural coverage of the M.tb proteome and the completely
different ligand binding poses, ligand binding site similarity is
necessary but not sufficient to determine the cross-reactivity
between two proteins for a specific ligand. The chemical nature of
the ligand also determines off-target binding. Although off-target
predictions based on similar ligand binding sites are invaluable for
the progressive design of selective or polypharmacological drugs,
they may result in false positive connections between proteins and
existing drugs. Thus, the TCDI may be not correlated with the
docking scores. The direct assessment of protein-drug interactions
using protein-ligand docking may solve part of this problem, but
success is not guaranteed due to the inaccuracy of docking scoring
functions. While free energy calculations based on molecular
dynamics simulations may improve the prediction of protein-
ligand interactions, they are computationally intensive and
currently impractical on a proteome-wide scale. It remains a
significant challenge to develop new methodologies for accurate
and efficient protein-ligand docking and free energy calculation for
the prediction of drug off-targets on a proteome-wide scale.
Molecular basis for the topological structure of drug-
target networks
It has been argued that drug-target networks are not modular
but random [1]. Drug-target networks constructed by linking all
drug-target pairs from annotated chemical libraries or computa-
tionally predicted results are limited and biased. Mestres et al.
discovered that the topologies of drug-target networks are
implicitly dependent on drug properties and target families [58].
Consequently, given the biased coverage of target families, the
topological properties observed in drug-target networks may not
necessarily reflect the inherent properties observed in proteome-
wide protein-ligand interaction networks. Here we suggest that
modularity does exist in our structural proteome-wide drug-target
network, and that it follows a power-law distribution. Any
observed randomness appears to result from the biased coverage
of drug targets. The power-law distribution has been observed in
many biological networks including protein-protein interaction
networks [59] and metabolic networks [60,61]. Recently, it has
been found that interaction networks between proteins and their
endogenous ligands follow a power-law distribution [62]. Such
connectivity distributions also appear in other man-made
networks, such as the World Wide Web and social networks.
The preferential attachment principle [63,64], which has been
tested in social networks, can be applied to biological networks
[62,65] according to the evolutionary history of ligands and
proteins. These studies have shown that evolutionarily ancient
ligands and proteins tend to have more connections. It follows that
the local structures of the binding site and the core fragments of
the ligand are more conserved than global structures and
sequences [66].
In the case of protein-ligand interaction networks, the structural
basis behind their power-law distribution and scale-free nature
could be the modularity of protein-ligand binding sites, the
modular arrangement of chemical fragments [67,68], and the
flexibility of both ligand [69] and protein structures [70]. By
studying the characterizing descriptors for ligands and small
molecules, Ji et al. found that polar molecular surface area, H-bond
donor counts, H-bond acceptor counts and partition coefficients
are key factors that can be used to discriminate hub ligands from
others [62].
A new concept to determine a target’s chemical
druggability
There are two aspects of target druggability; biological and
chemical. From a biological point of view, druggability is
conventionally based upon multiple criteria such as gene
essentiality, conservation across kingdoms, protein-protein inter-
actions, redundancy among pathways, endogenous metabolite
distributions, and coupling between metabolic, regulatory and
signalling pathways. However, a biologically druggable essential
gene is not necessarily chemically druggable because it may be
difficult to design a drug-like molecule to bind it with high affinity
and specificity. Thus, biologically validated drug targets need to be
linked to their chemical space as early as possible in order to
determine their chemical druggability. Although chemical drugg-
ability can be predicted from the ligand binding site of a protein
[26], there is still a big gap between identifying lead compounds
and developing safe drugs. The Target Chemical Druggability
Index (TCDI) proposed here is intended to bridge the target
validation process and medicinal chemistry efforts to select targets
that are both essential (as determined from other resources or
methodologies) and appropriate for use in the design of drug-like
molecules.
If the functional site of a single protein is connected to, and
could therefore potentially be inhibited by, one or more approved
drugs, this is a strong indication that this protein may be
chemically druggable. Moreover, if a protein has a high TCDI,
this implies that any new ligand found will likely occupy the
chemically constrained space of approved drugs, as opposed to the
essentially unlimited chemical space, and this could benefit drug
discovery in many ways. Firstly, it could narrow down the infinite
chemical space needed for high-throughput screening to identify
lead compounds. Secondly, it provides information about the
ligand binding site, which is critical for rational drug design.
Thirdly, it may reduce medicinal chemistry efforts to optimize the
lead compound as a drug candidate. Finally, and perhaps most
critical in this new era of drug discovery, it offers more
opportunities to design polypharmacological drugs, which may
not only improve drug efficacy and combat drug resistance, but
also minimize human side effects. By taking gene essentiality data,
chemical druggability information, ligand binding site informa-
tion, and the ligand coverage of drug space into account
simultaneously, the significant time and costs associated with
anti-infectious drug discovery and development could be signifi-
cantly reduced.
A search of the TDR target database [47] reveals that there are
no chemical compounds associated with any M.tb proteins with a
high TCDI other than InhA. Thus, the TB-drugome provides
abundant testable hypotheses for the development of new anti-
tubercular therapeutics. It is expected that the discovery of a drug
candidate by the targeted screening of these drugs will require a
fraction of the time and costs associated with conventional high-
throughput screening. Even if a drug shows weak activity in an
initial assay, the assay can be extended to include the large number
of analogues of that drug that have already been synthesized and
tested. In this way, it may be possible to discover a potent
compound that weakly inhibits the primary drug target, but
strongly binds to the M.tb target. Such a strategy has been
TB-Drugome
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inhibitors to target bacterial biotin carboxylase [25].
A concurrent versus linear drug discovery process
Conventional drug discovery and development proceeds as a
linear process from target identification and validation, to lead
discovery and optimization, to preclinical and clinical trials. It is
estimated that more than 90% of drug candidates fail during the
late stages of drug development, mainly due to poor efficacy or
safety [71]. If information were available about disease mecha-
nisms, target druggability, the chemical space of the target, the
pharmacokinetics and dynamic properties of drug candidates, and
their potential off-targets that may result in unwanted side effects
(or sometimes a desirable therapeutic effect), then their consider-
ation in drug development would help to optimize resource
allocation and improve productivity in the pharmaceutical
industry [72]. Proteome-wide multi-scale drug-target interaction
networks help here by providing a resource to unify disease, target,
and chemical space, thereby allowing the simultaneous assessment
of target essentiality, target druggability, drug design feasibility,
chemical availability, compound toxicity, and individual drug
response.
In the context of anti-infectious drug discovery, network analysis
can be used to identify critical nodes in molecular networks which
could represent novel drug targets [28] as illustrated here.
Moreover, it is believed that druggability and essentiality are best
assessed at the binding site level rather than the global sequence or
structural level [43]. Thus, the integration of ligand binding site
characterization with systems biology is critical for target
identification and prioritization. Even if druggability can be
assessed by analyzing the ligand binding site of the target, there is
still a huge gap between identifying hit compounds and producing
drug candidates. Moreover, the drug candidate may not be safe for
human use due to undesirable ADME properties or unwanted off-
target effects. By bridging target and drug space, drug-target
interaction networks provide invaluable information about the use
of existing drugs as lead compounds. In an ideal situation, the drug
can be repositioned directly to target the intended target in the
pathogen, hence promising a solution to reduce both the time and
costs associated with drug development [73]. Since the drugs have
already been approved for human use, it is possible to bypass
toxicological and pharmacokinetic assessments, which together
contribute approximately 40% of the overall cost of bringing a
new drug to market. Newly identified drug indications can be
evaluated relatively quickly in phase II clinical trials, which
typically only take two years and cost around $17 million [74,75].
Conclusions
The continuing emergence of M.tb strains that are resistant to all
existing affordable drug treatments means that the development of
novel, effective and inexpensive drugs is an urgent priority [15,76].
However, current drug discovery methods appear inadequate in
the battle against infectious diseases such as tuberculosis [74].
Drug repositioning provides a promising solution to reduce both
the time and costs associated with drug development [73]. We
have developed a computational approach to compare the binding
sites of a subset of existing drugs approved for human use against
the entire M.tb structural proteome. In this way, it is possible to
identify putative new targets of existing drugs within the M.tb
proteome, providing the basis for their repositioning to treat
tuberculosis. Our drug-target interaction network, the TB-
drugome, revealed not only that many existing drugs show the
potential to be repositioned to treat tuberculosis, but also that
some drugs show the potential to be multi-target inhibitors. This is
beneficial since multi-target therapy is thought to be more effective
than single-target therapy when treating infectious diseases [77].
In addition, the TB-drugome suggests that a large number of M.tb
proteins are potentially druggable and could therefore serve as
novel drug targets in the fight against tuberculosis. We provide the
TB-drugome (http://funsite.sdsc.edu/drugome/TB) for analysis
by others.
Methods
Structural coverage of the M.tb proteome
There are 3,996 proteins in the M.tb proteome, 284 of which
have solved structures in the RCSB PDB (November 5, 2009).
Although this approximates to only 7.2% structural coverage of
the M.tb proteome, it is worth noting that there is likely to be a
strong bias towards those targets being relevant to drug discovery.
There are multiple structures available for many of these proteins
(i.e., a single protein may have been solved with a number of
different ligands), bringing the total of solved M.tb structures to 749
(November 5, 2009) (see Table S4 in the Supporting Information
for further details). It was decided that all 749 of these structures
should be used in this study, since a single protein may exhibit
multiple binding modes and such information would be missed if
only a single structure was chosen to represent each of the 284
proteins. It is important to note that the whole biological unit,
rather than a single chain of each structure was used in the case of
experimental structures so as to capture ligand binding sites at the
interface between polypeptide chains.
ModBase [78], a database of annotated comparative protein
structure models, contains homology models for the entire M.tb
proteome. However, since they are derived from an automated
pipeline, it is likely that some of these models may contain
significant errors. Each model in ModBase has been assigned a
score corresponding to its reliability, which is derived from
statistical potentials. A model is predicted to be reliable if its model
score is greater than 0.7 and its ModPipe Protein Quality Score
(MPQS) is greater than 1.1 (http://modbase.compbio.ucsf.edu/
modbase/modbase_help.html). By employing these thresholds, it
is possible to discard unreliable models. ModBase was found to
contain ‘reliable’ homology models for a total of 1,446 unsolved
M.tb proteins (see Table S5 in the Supporting Information for
further details). Through the additional use of these reliable
homology models, the structural coverage of the M.tb proteome
was increased to around 43%. However, only a single chain of
each homology model was available, rather than the entire
biological unit.
Identification of FDA-approved drug binding sites
Drugs approved for human use in the United States and Europe
are listed in the U.S. Food and Drug Administration (FDA) Orange
Book (http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm)
and by the European Medicines Agency (EMEA) (http://www.emea.
europa.eu/htms/human/epar/a.htm), respectively. The names of
t h ea c t i v ei n g r e d i e n t so ft h e s ed r u g sw e r ee x t r a c t e da n dm a p p e dt o
compounds in three databases; PubChem (http://pubchem.ncbi.
nlm.nih.gov/), DrugBank [13,79] (http://www.drugbank.ca/) and
ChEBI (http://www.ebi.ac.uk/chebi/). After removing all nutraceu-
ticals and prodrugs, InChI keys were used to map the remaining
compounds to protein crystal structures in the PDB. Non-protein
crystal structures such as DNA, RNA and ribosomes were excluded.
274 different drugs were identified bound to a total of 962 different
protein binding sites (November 30, 2009). A full list of the approved
drug binding sites used in this study is provided in the Supporting
Information, Table S1.
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Xie et al. recently developed the ligand binding site comparison
software SMAP [22], which is based on a sequence order
independent profile-profile alignment (SOIPPA) algorithm [24].
Firstly, the protein structure is characterized by a geometric
potential; a shape descriptor that is analogous to surface
electrostatic potential, but which uses a reduced C-alpha only
structural representation of the protein. It has been shown that
both the location and the boundary of the ligand binding site can
be accurately predicted using the geometric potential [23]. The
reduced representation of the protein structure makes the
algorithm tolerant to protein flexibility and experimental uncer-
tainty; thus SMAP can be applied to low-resolution structures and
homology models. Secondly, two protein structures are aligned,
independent of sequence order, using a fast, maximum weighted
sub-graph (MWSG) algorithm [80,81]. The MWSG finds the most
similar local structures in the spirit of local sequence alignment.
Finally, the aligned surface patches are ranked by a scoring
function that combines evolutionary, geometric and physical
information. The statistical significance of the binding site
similarity is then rapidly computed using a unified statistical
model derived from an extreme value distribution [22].
The SMAP software was used to compare the binding sites of
the 749 M.tb protein structures plus 1,446 homology models (a
total of 2,195 protein structures) with the 962 binding sites of 274
approved drugs, in an all-against-all manner. While the binding
sites of the approved drugs were already defined by the bound
ligand, the entire protein surface of each of the 2,195 M.tb protein
structures was scanned in order to identify alternative binding
sites. For each pairwise comparison, a P-value representing the
significance of the binding site similarity was calculated.
Comparison of global protein structures using FATCAT
FATCAT (Flexible structure AlignmenT by Chaining Aligned
fragment pairs allowing Twists) [82] is a program for the flexible
comparison of protein structures. It optimizes the alignment
between two structures, whilst minimizing the number of rigid
body movements (twists) around pivot points introduced in the
reference structure. In addition to the optimal structural
alignment, FATCAT reports the statistical significance of the
structural similarity, measured as a P-value. In order to identify
pairs of similar binding sites that were from proteins with
dissimilar global structures (i.e., cross-fold connections), the first
chain of each PDB file was aligned using FATCAT, and those
pairs with a significant P-value of less than 0.05 were discarded.
Visualization of the protein-drug interaction network
yEd Graph Editor from yWorks (http://www.yworks.com/en/
products_yed_about.html) was used to visualize the drug-target
interaction network. M.tb protein names were taken from the
NCBI Entrez protein database (http://www.ncbi.nlm.nih.gov/
protein), to avoid inconsistencies in the naming of proteins in the
PDB.
Flux balance analysis
GSMN-TB [27], a web-based genome-scale network model of
M.tb metabolism was used to carry out flux balance analysis (FBA)
computations. The GSMN-TB model contains 739 metabolites
and 726 genes that are involved in 849 unique reactions. For those
M.tb genes of interest that were also present in the GSMN-TB
model, the single gene knockout tool was used to run essentiality
prediction under conditions optimized for in vivo growth. If the
resulting maximal theoretical growth rate was zero or close to
zero, then a gene was predicted to be essential, whereas if it was
the same as wildtype (0.050191 mmol/g DW/h), it was predicted
to be non-essential. In order to simulate multiple gene knockouts,
the reactions in which these genes were involved were constrained
by setting their upper and lower bound values to zero. Note that
this was only carried out for those reactions that could not be
carried out by any other genes, i.e., those that were entirely
dependent on the gene of interest.
iNJ661 [28] is another genome-scale metabolic reconstruction
of M.tb that contains 828 metabolites and 661 genes which are
involved in 939 reactions. In order to determine in vitro essentiality
we used the COBRA Toolbox [83] to perform single gene
deletions on the iNJ661 model grown in Middlebrook 7H9 media.
Again, genes were predicted to be essential if the maximal
theoretical growth rate resulting from their deletion was zero or
close to zero.
Molecular docking using eHiTS
For those pairs of interest, molecular docking was used to
predict the binding pose and affinity of the drug molecule to the
M.tb protein. eHiTS Lightning [84] was selected due to its fast
speed, relatively high accuracy and ease of automation for large-
scale docking studies. Since SMAP had aligned the drug binding
site with the M.tb protein binding site, the aligned coordinates of
the drug molecule were used to define the search space for docking
that drug into the M.tb protein. The aligned drug molecule was
used as the clip file with a default search space of 10A ˚ 3.A s
recommended by the manual, the eHiTS accuracy level was set to
6 (default =3), in order to increase the accuracy of the predicted
binding poses. Following all docking, the binding pose with the
lowest estimated binding affinity was selected for further
investigation. For those proteins with cofactors (e.g., InhA has
an NAD cofactor), the cofactor was added as the last residue in the
protein structure prior to docking.
Network analysis
The drug-target interaction network can be represented as a
graph. The number of targets or drugs against their connectivity in
the graph can be fitted to a power-law distribution, where:
y~axk
y and x are the number of targets or drugs and their connectivity,
respectively, and a and k are two fitted parameters.
A protein graph was constructed for the drug-target network.
Nodes represented proteins and edges were formed between two
protein nodes if they were connected to the same drug. Then the
fraction of the largest connected component (nLCC) of the
protein was computed by dividing the number of proteins in the
largest single linkage cluster by the total number of proteins in the
graph. The nLCC values of drugs can be computed in a similar
manner.
Hierarchical clustering of protein and drug binding
profiles
Protein and drug binding profiles in the TB-drugome were
hierarchically clustered using GenePattern 2.0 [85]. The
distance between the profiles was measured using the city block
distance.
Comparison of drug chemical similarity
The 2D fingerprint similarity of drugs was computed using
OpenBabel 2.1.1 (http://openbabel.org).
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Figure S1 Fitting of the distribution of drug connections to a
power-law distribution for co-crystallized drug complexes in the
PDB.
Found at: doi:10.1371/journal.pcbi.1000976.s001 (0.15 MB
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Figure S2 Fitting of the distribution of drug connections to a
power-law distribution for the TB-drugome and a random
network.
Found at: doi:10.1371/journal.pcbi.1000976.s002 (1.06 MB
DOC)
Figure S3 Fraction of the largest connected component (nLCC)
in the network for the TB-drugome and a random network at
different SMAP P-value thresholds.
Found at: doi:10.1371/journal.pcbi.1000976.s003 (0.05 MB
DOC)
Figure S4 The clustering coefficient of the TB-drugome derived
from different fractions of structurally characterized drugs.
Found at: doi:10.1371/journal.pcbi.1000976.s004 (0.07 MB
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Figure S5 Predicted drug binding site and poses in adenylyl
cyclase.
Found at: doi:10.1371/journal.pcbi.1000976.s005 (0.75 MB
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Table S1 Information about the approved drug binding sites
used in the TB-drugome. This file contains information about the
274 approved drugs that were identified in the PDB. For each
drug, its name, PDB ligand code, isomeric SMILES string and
known targets are listed, and the PDB codes of the protein
structures with which it has been crystallized are given.
Found at: doi:10.1371/journal.pcbi.1000976.s006 (0.09 MB XLS)
Table S2 Cross-fold drug-target pairs in the TB-drugome (for
solved M.tb structures only). This file contains a list of the cross-
fold drug-target pairs with a SMAP P-value ,1.0e-5, for solved
M.tb structures only. For each pair, information about the drug
and target structures is given, as well as the corresponding SMAP
P-value (indicating the significance of the binding site similarity)
and eHiTS energy score (from docking the drug into the predicted
binding site in the M.tb protein).
Found at: doi:10.1371/journal.pcbi.1000976.s007 (0.08 MB XLS)
Table S3 Cross-fold drug-target pairs in the TB-drugome (for
M.tb homology models only). This file contains a list of the cross-
fold drug-target pairs with a SMAP P-value ,1.0e-5, for
homology models of M.tb proteins only. For each pair,
information about the drug and target structures is given, as well
as the corresponding SMAP P-value (indicating the significance of
the binding site similarity) and eHiTS energy score (from docking
the drug into the predicted binding site in the M.tb protein).
Found at: doi:10.1371/journal.pcbi.1000976.s008 (0.15 MB XLS)
Table S4 Information about the solved M.tb structures used in
the TB-drugome. This file contains information about the M.tb
proteins with solved structure(s) in the RCSB PDB that were used
in the the TB-drugome. For each protein, the gene name (if
available), gene accession number, protein name and correspond-
ing PDB codes are given.
Found at: doi:10.1371/journal.pcbi.1000976.s009 (0.06 MB XLS)
Table S5 Information about the M.tb homology models used in
the TB-drugome. This file contains information about the reliable
homology models of M.tb proteins from ModBase that were used in
TB-drugome. For each homology model, the ModBase model code
is given, as well as the gene accession number, gene name and
description of the M.tb protein. N.B. Further information about
each homology model can be found on the ModBase website.
Found at: doi:10.1371/journal.pcbi.1000976.s010 (0.24 MB XLS)
Table S6 Parameters to fit the power law distribution for drug
connections in the TB-drugome.
Found at: doi:10.1371/journal.pcbi.1000976.s011 (0.03 MB
DOC)
Table S7 Parameters to fit the power law distribution for target
connections in the TB-drugome derived from the fraction of
structurally characterized drugs.
Found at: doi:10.1371/journal.pcbi.1000976.s012 (0.03 MB
DOC)
Table S8 Parameters to fit the power law distribution for drug
connections in the TB-drugome derived from the fraction of
structurally characterized drugs.
Found at: doi:10.1371/journal.pcbi.1000976.s013 (0.03 MB
DOC)
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